Indoco Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies reported Q1 FY26 standalone revenue of ₹383.8 crore, up 12.5% sequentially from ₹341.1 crore in Q4 FY25, but down about 2.6% from ₹394.2 crore in Q1 FY25. Despite the sequential revenue improvement, the company swung to a standalone loss of ₹28.1 crore versus a profit of ₹15.0 crore a year ago, with EPS at ₹(3.04) versus ₹1.62. On a consolidated basis, revenue was ₹429.1 crore versus ₹424.3 crore YoY, with a loss after tax of ₹36.4 crore versus a small profit of ₹1.8 crore earlier. The auditor (Gokhale & Sathe) issued an unmodified opinion but flagged an Emphasis of Matter regarding two subsidiaries — FPP Holding LLC and Warren Remedies Pvt Ltd — both of which have negative net worth and may face going-concern uncertainty, though the parent did not book any impairment.
Negative near-term sentiment likely as the company reported a YoY loss despite stable revenues, driven by higher finance costs and employee/other expenses. However, the sequential revenue recovery, EBITDA improvement to ₹148 mn from ₹35 mn, and the parent's own net worth remaining positive offer some comfort. Investors should watch the parent's exposure to its loss-making subsidiaries, especially FPP Holding and Warren Remedies, as further deterioration there could trigger impairments.